Investigating how metabolites affect cancer through a specific enzyme
Metabolite sensing through the HAT1 acetyltransferase as an anti-cancer target
['FUNDING_CAREER'] · UT SOUTHWESTERN MEDICAL CENTER · NIH-10851955
This study is looking at how a specific enzyme called HAT1 affects cancer growth and how what we eat might change how cancer cells behave, with the hope of finding new ways to treat cancer that could help patients like you.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UT SOUTHWESTERN MEDICAL CENTER (nih funded) |
| Locations | 1 site (DALLAS, UNITED STATES) |
| Trial ID | NIH-10851955 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of the HAT1 enzyme in cancer development and progression. The principal investigator, Dr. Joshua Gruber, aims to explore how metabolites, particularly those derived from dietary sources, influence cancer cell behavior and gene expression. By identifying potential activators and inhibitors of HAT1, the research seeks to uncover new therapeutic targets for treating various malignancies. Patients may benefit from insights that could lead to innovative cancer treatments based on dietary influences on metabolism.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with early or advanced stage malignancies, particularly those interested in novel treatment approaches.
Not a fit: Patients with non-cancerous conditions or those not diagnosed with malignancies may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new cancer therapies that target metabolic pathways, improving treatment options for patients.
How similar studies have performed: Other research has shown promise in targeting metabolic pathways for cancer treatment, suggesting that this approach could lead to significant advancements.
Where this research is happening
DALLAS, UNITED STATES
- UT SOUTHWESTERN MEDICAL CENTER — DALLAS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GRUBER, JOSHUA JAMES — UT SOUTHWESTERN MEDICAL CENTER
- Study coordinator: GRUBER, JOSHUA JAMES
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents